Finally, for patients with non-rhabdomyolysis-inducedAKI, a cautious attitude should be adopted in considering PCSK9 inhibitors asstatin alternative therapy, given the presence of, rare, case reports of PCSK9inhibitor-induced AKI [60, 61]. This evidence concerns the gene PCSK9 and acute kidney injury.